Evotec and Odyssey Therapeutics have entered into a strategic Autoimmune R&D Partnership aimed at advancing novel therapeutic candidates for complex biological targets. The initiative focuses on discovering novel options for autoimmune and inflammatory disease treatments by integrating specialized disease biology with advanced experimental capabilities.
Integrating Experimental and Data Science Capabilities
Under the terms of the agreement, Odyssey Therapeutics will utilize Evotec’s proprietary drug discovery platform. This platform combines extensive compound libraries and advanced screening capabilities with machine learning-driven analysis and AI-enabled data science technologies. By leveraging high-throughput experimentation alongside data-driven insights, the companies seek to discover and validate differentiated small molecule drug candidates across multiple high-value targets.
The approach is designed to accelerate the identification of validated hit series and support the swift progression of early-stage research programs into potential therapeutic options.
Strategic Alignment and Discovery Goals
Speaking on the strategic approach, Evotec Chief Scientific Officer Cord Dohrmann, PhD, noted that drug discovery increasingly relies on uniting deep disease biology with modern experimental platforms.
“This collaboration with Odyssey illustrates well Evotec’s strategy in applying integrated discovery platform technologies to complex disease areas,” Dohrmann stated. “We aim to generate differentiated, validated starting points for Odyssey to develop into new therapies for autoimmune and inflammatory diseases.”
Through this partnership for autoimmune and inflammatory diseases, both organizations aim to combine complementary technological and scientific capabilities to enhance early-stage drug development. The effort focuses on delivering scalable starting points aimed at advancing future inflammatory disease treatments.
Structure of the Financial Agreement
While specific financial figures were not disclosed, the agreement establishes that Evotec is eligible for milestone payments tied to performance. These payments are contingent upon the successful delivery of validated hit series for each specified target, structuring the collaboration to link value creation directly to drug discovery achievements through their shared drug discovery platform.
